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Purpose: Toll-like receptors (TLRs) are pattern-recognition receptors that play an important role in innate and adaptive
immune responses to microbial pathogens. Among TLRs, TLR4 recognizes lipopolysaccharides of Gram-negative
bacteria. Genetic polymorphisms within the TLR4 gene have been reported to be associated with various inflammatory
diseases; therefore, TLR4 appears to be a susceptibility gene for sarcoidosis. Although sarcoidosis has various clinical
manifestations, its association with uveitis is more common in Japan than in other countries. The aim of this study was to
investigate whether TLR4 polymorphisms were associated with sarcoidosis-related uveitis in a Japanese population.
Methods: Two hundred twenty-three patients with sarcoidosis and 206 healthy control subjects were recruited at seven
sites in Japan. Eight single-nucleotide polymorphisms (SNPs) in TLR4 were genotyped with a TaqMan assay, and allelic
and phenotypic diversity were assessed in affected and control subjects.
Results: We found no association with susceptibility to sarcoid-related uveitis for any of the SNPs analyzed. Strong
linkage disequilibrium was observed among all the SNPs analyzed (D’≥0.78), which were located in one haplotype block.
Conclusion: TLR4 polymorphisms do not play an important role in the development of uveitis in Japanese patients with
sarcoidosis.
Sarcoidosis  is  a  systemic  inflammatory  syndrome  of
unknown  etiology  characterized  by  the  accumulation  of
immune effector cells in affected organs, such as lungs, lymph
nodes,  eyes,  skin,  and  heart.  The  severity  and  mode  of
presentation  are  influenced  by  ethnicity.  For  instance,
Löfgren’s syndrome, an acute form of sarcoidosis, is more
common  among  Caucasians,  and  a  more  serious  form  of
sarcoidosis has been observed in patients of African descent
[1,2]. The incidence of ocular involvement is higher in Japan
(50-93.5%) compared to that of other countries (25-60%)
[2-8].  Clinically,  ocular  manifestations  in  sarcoidosis  are
considered bilateral, chronic, granulomatous uveitis [9]. The
variety  of  clinical  manifestations  of  sarcoidosis  and  the
observed dependence on race and familial clustering suggest
there  may  be  a  genetic  predisposition  for  developing
sarcoidosis [10-12]. Numerous studies have reported genetic
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associations  between  various  major  histocompatibility
complex (MHC) genes and the susceptibility, severity, and
presentation of sarcoidosis [13-17]. The first genome-wide
search for genes that predispose for sarcoidosis in German
families used microsatellite linkage analysis. These studies
identified several chromosomal regions that contributed to the
risk  of  sarcoidosis.  The  MHC  genes  displayed  the  most
prominent  signal  in  these  regions.  This  supported  the
hypothesis that MHC genes were associated with the different
manifestations  of  sarcoidosis  [18].  Furthermore,  another
genome-wide  association  study  that  included  >440,000
single-nucleotide  polymorphisms  (SNPs)  in  patients  with
sarcoidosis also reported a series of genetic associations [19].
It  has  been  suggested  that  sarcoidosis  results  from
exposure  of  genetically  susceptible  hosts  to  specific,  but
unidentified environmental agents [20]. The granuloma in
sarcoidosis develops, in general, as a response to a persistent,
weakly virulent antigen(s) that induces a local helper T cell
type 1 (Th1) immune response [21].
Toll-like receptors (TLRs) are transmembrane proteins
that function as pattern-recognition receptors (PRRs) in innate
immunity.  TLRs  also  provide  a  link  to  the  activation  of
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2673adaptive immunity by recognizing microbial components and
inducing the production of cytokines, such as Interleukin 12
(IL12) and IL18 driving naïve T cells to differentiate into Th1
cells [22]. Among TLR family members, TLR4 is expressed
in a wide variety of human cells, where it plays an important
role  in  innate  and  adaptive  immune  responses  to  Gram-
negative  bacterial  products,  including  lipopolysaccharides
[22,23].
In  recent  studies,  TLR4  polymorphisms  have  been
reported to be associated with various inflammatory diseases,
including atherosclerosis, Crohn’s disease, ulcerative colitis,
rheumatoid arthritis, prostate cancer, and Alzheimer’s disease
[23-28]. These findings suggest that genetic variants of TLR4
that  have  abnormal  ligand  recognition  properties  may
contribute to the development of various diseases, including
sarcoidosis.
Due to its various clinical manifestations, sarcoidosis is
often considered to be a family of disorders with clinically and
genetically different phenotypes, rather than a single entity
[29]. This study investigated whether TLR4 polymorphisms
were  associated  with  susceptibility  to  sarcoidosis-related
uveitis in Japanese patients.
METHODS
Subjects:  This  study  included  223  Japanese  patients  with
sarcoidosis  (52  men  and  171  women)  and  206  healthy
Japanese controls (48 men and 158 women) from Yokohama
City  University,  Hokkaido  University,  Fujita  Health
University,  Tokyo  University,  Keio  University,  the
Kumamoto City hospital, and the Yuasa Eye Clinic. All 223
patients  had  chronic  sarcoidosis;  68  cases  were  clinically
diagnosed and 155 cases were confirmed by biopsies. These
223 patients were divided into two groups: 196 (87.9%) with
uveitis (the sarcoid-uveitis group) and 27 (12.1%) without
uveitis (the sarcoid non-uveitis group). Clinical sarcoidosis
was diagnosed according to the diagnostic criteria developed
by  the  Japanese  Society  of  Sarcoidosis  and  Other
Granulomatous Disorders (JSSOG) in 1977 [9]. Uveitis with
sarcoidosis  was  assessed  based  on  the  Guidelines  for
Diagnosis of Ocular Lesions in Sarcoidosis prepared by the
JSSOG. The ocular features of sarcoidosis were defined as
granulomatous uveitis plus two or more of the following:
infiltration  of  the  anterior  chamber  (mutton-fat  keratic
precipitates/iris nodules), trabecular meshwork nodules and/
or tent-shaped peripheral anterior synechia, masses of vitreous
opacities (snowball-like or string of pearls-like appearance),
periphlebitis with perivascular nodules; multiple candle-wax
type  chorioretinal  exudates  and  nodules,  and/or  laser
photocoagulation spot-like chorioretinal atrophy [30].
All the control subjects were unrelated healthy volunteers
that were ethnically similar to the patients. The study obtained
the  approval  of  the  Ethics  Committee  of  Yokohama  City
University School of Medicine, and was in compliance with
the guidelines of the Declaration of Helsinki. Details of the
study were explained to all patients and controls, and written
informed consent was obtained for genetic screening.
Analysis of TLR4 polymorphisms: The QIAamp DNA Blood
Maxi Kit (Qiagen, Tokyo, Japan) was used to extract genomic
DNA from peripheral blood cells. Procedures were performed
under standardized conditions to prevent variation in DNA
quality.
The TLR4 gene is located on chromosome 9q32-q33. We
evaluated  eight  single-nucleotide  polymorphisms  (SNPs),
including: rs10759930, rs1927914, rs1927911, rs12377632,
rs2149356, rs11536889, rs7037117, and rs7045953 within
TLR4. These SNPs were selected based on previous reports
[31-33] and information from public sources, including the
NCBI dbSNP, ABI, and HapMap databases. The selected
SNPs had minor allele frequencies that were >5% (Table 1).
Each SNP was approximately 1 to 5 kb long, and the set of
SNPs  spanned  TLR4,  from  approximately  5  kb  of  the
predicted 5’-untranslated region (UTR) to approximately 6 kb
of  the  predicted  3’  UTR.  Genotyping  of  the  SNPs  was
performed  with  the  TaqMan  5’  exonuclease  assay  using
primers supplied by ABI (Foster City, CA). The probe emitted
a fluorescent signal and was incorporated during the TaqMan
Assay for Real-Time PCR (7500 Real Time PCR System;
Applied  Biosystems),  following  the  manufacturer’s
instructions.
Statistical analysis: The Hardy-Weinberg equilibrium (HWE)
was tested for each SNP in cases and controls. Differences in
allele frequencies between cases and controls were assessed
with the χ2 test or Fisher’s exact test. The Haploview 3.32
program was used to compute pairwise linkage disequilibrium
(LD) statistics [34]. Standardized disequilibrium D’ and r2
were plotted. LD blocks were defined according to the criteria
of Gabriel et al. [35]. Haplotype frequencies were estimated
with  an  accelerated  expectation-maximization  algorithm,
similar  to  the  partition-ligation-expectation-maximization
method described previously [36]. All p-values were derived
from  a  2-sided  test,  and  p-values  <0.05  were  considered
statistically significant.
RESULTS
Eight SNPs in TLR4 were genotyped. All SNPs were in HWE
among both cases and controls (data not shown). All eight
SNPs were located in one haplotype block, and the magnitude
of LD between each SNP was extremely high, with pair-wise
D’ values that were ≥0.78 (Figure 1).
Table 1 shows the details of the eight SNPs, including
their genomic locations and minor allele frequencies in cases
and  controls.  No  statistically  significant  association  was
observed for any of the SNPs between the sarcoid uveitis
group and the sarcoid non-uveitis group, between the sarcoid
uveitis group and the control subjects, or between the sarcoid
non-uveitis group and the control subjects (p≥0.05; Table 1).
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in Table 2, Table 3, and Table 4. There were no differences in
the minor allele frequency of each SNP between the sarcoid
uveitis group and the sarcoid non-uveitis group, between the
sarcoid uveitis group and the control subjects, or between the
sarcoid non-uveitis group and the control subjects (p≥0.05;
Table 2, Table 3, and Table 4).
Furthermore, there were no significant differences in the
haplotype frequencies of the eight SNPs between the sarcoid
uveitis group and the sarcoid non-uveitis group, between the
sarcoid uveitis group and the control subjects, or between the
sarcoid non-uveitis group and the control subjects (p≥0.05;
Table 5)
DISCUSSION
In  this  study,  we  investigated  whether  there  were  any
associations between TLR4 polymorphisms and uveitis with
sarcoidosis. We found no associations for any of the SNPs
analyzed.  Several  infectious  organisms,  including
mycobacteria,  mycoplasma,  propionibacteria,  and
cytomegalovirus, have been proposed as potential causes of
sarcoidosis [20,37,38]. The mycobacterium tuberculosis heat
shock  proteins  (Mtb-HSPs)  have  also  been  suggested  as
causative agents of sarcoidosis based on the cross-reactivity
observed between mycobacterial and human HSPs [39,40]. A
SNP within the HSP-70/Hom gene was identified as a factor
associated with susceptibility to sarcoidosis [41]. Others have
also reported that SNPs in HSP-70/1 and HSP-70/Hom were
associated with sarcoid-related uveitis [29]. TLR4 recognizes
endogenous ligands, including heat shock proteins (HSP60,
HSP70) and exogenous ligands; upon binding these ligands,
TLR4 induces the production of proinflammatory cytokines
[22,42,43]. Therefore, it was hypothesized that TLR4 and its
ligands  would  be  implicated  in  the  development  of
sarcoidosis.  The  results  of  this  study  do  not  support  that
hypothesis.
The long arm of chromosome 9, which harbors TLR4, was
identified as a region related to the susceptibility to sarcoidosis
by genome-wide microsatellite linkage analysis in a German
population [18]. This suggested that TLR4 polymorphisms
were  associated  with  sarcoidosis.  Two  different  SNPs  in
TLR4,rs4986790 (Asp299Gly) and rs4986791 (Thr399Ile),
affected the extracellular domain of the TLR4 receptor. These
were  reported  to  be  associated  with  the  development  of
chronic  sarcoidosis  in  a  German  case  control  study  [44].
However, the results could not be replicated in Dutch and
Greek populations [45,46]. Previously, we analyzed the same
Figure  1.  Structure  of  linkage
disequilibrium  (LD)  plotted  for  eight
SNPs in the TLR4 gene. The D’ value
and  r2  value  (in  parentheses)  that
correspond  to  each  SNP  pair  are
expressed as a percentage and shown
within  the  respective  square.  The
gradient  of  D’  values  (low  to  high
values) is indicated by different shades
of red (light to dark, respectively). The
eight SNPs constitute a haplotype block
that spans 24 kb of TLR4.
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2679SNPs in TLR4 that were examined in this study to determine
whether they were associated with susceptibility to Behçet's
disease (BD) and normal tension glaucoma [31,32]. In that
study, we found that the SNP, rs7037117, located in the 3’-
untranslated region, was significantly associated with BD and
normal tension glaucoma. We also explored the same SNPs
to determine associations to BD in a Korean population. We
found the most frequent occurring haplotype was significantly
increased in patients with BD that were positive for HLA-
B*51 and in patients with BD and arthritis [33]. It was also
reported  that  two  non-synonymous  TLR4  SNP  sites,
Asp299Gly  (rs4986790)  and  Thr399Ile  (rs4986791),  were
associated  with  elevated  serum  cytokines  in  a  Caucasian
population [26]. However, no studies have detected these non-
synonymous  mutations  in  Asian  populations,  including
Koreans  [47].  Thus,  we  did  not  examine  those  two  non-
synonymous  SNPs  because  they  were  monomorphic  in  a
Japanese population. Our results showed no differences in
allelic diversity among patients that had sarcoidosis with or
without uveitis and healthy control subjects. However, our
results could not completely rule out the possibility that the
TLR4 signaling pathway plays a role in the development of
uveitis in patients with sarcoidosis. Although the discrepancy
between our results and those of the German study on chronic
sarcoidosis might be explained by racial differences, it will be
necessary to confirm this negative association in future studies
with larger cohorts.
In  conclusion,  the  present  study  showed  that  TLR4
polymorphisms  were  not  significantly  associated  to  the
development  of  uveitis  with  sarcoidosis  in  the  Japanese
population.
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